Identification of Differentially Expressed Genes in Different Glioblastoma Regions and Their Association with Cancer Stem Cell Development and Temozolomide Response
The molecular heterogeneity of gene expression profiles of glioblastoma multiforme (GBM) are the most important prognostic factors for tumor recurrence and drug resistance. Thus, the aim of this study was to identify potential target genes related to temozolomide (TMZ) resistance and GBM recurrence....
Guardado en:
Autores principales: | Justin Bo-Kai Hsu, Tzong-Yi Lee, Sho-Jen Cheng, Gilbert Aaron Lee, Yung-Chieh Chen, Nguyen Quoc Khanh Le, Shiu-Wen Huang, Duen-Pang Kuo, Yi-Tien Li, Tzu-Hao Chang, Cheng-Yu Chen |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c8ef5cf1ce0c4db6b4e32d215e18894d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Interplay of m6A and histone modifications contributes to temozolomide resistance in glioblastoma
por: Fuxi Li, et al.
Publicado: (2021) -
The PI3K Inhibitor XH30 Enhances Response to Temozolomide in Drug-Resistant Glioblastoma via the Noncanonical Hedgehog Signaling Pathway
por: Ming Ji, et al.
Publicado: (2021) -
Olaparib Is a Mitochondrial Complex I Inhibitor That Kills Temozolomide-Resistant Human Glioblastoma Cells
por: Luca X. Zampieri, et al.
Publicado: (2021) -
Accurately Controlled Delivery of Temozolomide by Biocompatible UiO-66-NH2 Through Ultrasound to Enhance the Antitumor Efficacy and Attenuate the Toxicity for Treatment of Malignant Glioma
por: Wan Z, et al.
Publicado: (2021) -
Combined Delivery of Temozolomide and siPLK1 Using Targeted Nanoparticles to Enhance Temozolomide Sensitivity in Glioma
por: Shi H, et al.
Publicado: (2020)